Image Credit:J Cell Mol Anesth
Outline
Introducing Markers which are Involved in COVID-19 Disease: Severe Condition Versus Mild State, a Network Analysis
Authors
Abstract
Background: Coronavirus disease 2019 (COVID-19) had a pandemic spread worldwide. Most infected patients had a good prognosis, but some developed severe illnesses, which led to fatalities. It is urgent to define markers that reveal the severity of the disease. This study aimed to introduce the main plasma protein biomarkers involved in severe conditions versus mild infection states.
Materials and Methods: A total of 91 significant differentially expressed proteins (DEPs) in the sera of the patients with the severe condition versus mild states were extracted from an original article. The protein interaction is included in a network designed via STRING database and Cytoscape software to find the critical proteins which differentiate severe conditions versus mild states.
Results: A total of 6 hub nodes identified as critical target proteins were APOB, SERPINA1, CP, ORM1, HASPA8, and VW, according to the Degree value of nodes.
Conclusion: The expression of different biomarkers in the sera of COVID-19 patients can be considered differential markers that separate severe conditions from mild states; however, a more thorough investigation is required.
Highlights
References
- 1.References are in the PDF file of the article.
Copyright
© 2022, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Similar Articles
Introducing Markers which are Involved in COVID-19 Disease: Severe Condition Versus Mild State, a Network Analysis
Mansouri V, Rezaei-Tavirani M, okhovatian F, Abbaszadeh HA. Introducing Markers which are Involved in COVID-19 Disease: Severe Condition Versus Mild State, a Network Analysis. J Cell Mol Anesth. 2021;6(4):e149740. doi: https://doi.org/10.22037/jcma.v6i4.35656
Differential Diagnostic Utility of Clinical Laboratory Data in Patients with Severe and Non-severe COVID-19
Hosseinzadeh A, Emamian MH, Rohani-Rasaf M, Khosravi A, Zare F, et al. Differential Diagnostic Utility of Clinical Laboratory Data in Patients with Severe and Non-severe COVID-19. Shiraz E-Med J. 2021;23(1):e113670. doi: https://doi.org/10.5812/semj.113670
Evaluation of Chemokines and Cytokines as Biomarkers for Disease Severity in COVID-19-Infected Patients
Karimi R, Mohamadnia A, Hosseini F, Bahrami N, Jamaati H. Evaluation of Chemokines and Cytokines as Biomarkers for Disease Severity in COVID-19-Infected Patients. Jundishapur J Microbiol. 2024;17(1):e143611. doi: https://doi.org/10.5812/jjm-143611
IP-10, MIP1α, IL-6, and IL-1β as Biomarkers Associated with Disease Severity of COVID-19
Paikar S, Bahrami N, Rafiei Tabatabai R, Mohamadnia A. IP-10, MIP1α, IL-6, and IL-1β as Biomarkers Associated with Disease Severity of COVID-19. Jundishapur J Microbiol. 2024;17(5):e144812. doi: https://doi.org/10.5812/jjm-144812
Investigation of Biochemical and Inflammatory Markers in COVID-19 Patients Hospitalized in the Intensive Care Unit: An Observational Study in Northern Iran
Khodabakhshi B, Mehghani M, Lashkarbolouk N, Golsha R, Besharat S, et al. Investigation of Biochemical and Inflammatory Markers in COVID-19 Patients Hospitalized in the Intensive Care Unit: An Observational Study in Northern Iran. Compr Health Biomed Stud. 2024;2(3):e149303. doi: https://doi.org/10.5812/chbs-149303
- Scopus by DOI: 3
Last Update: 1 month ago
- Scopus by Title: 3
Last Update: 1 month ago
- Scopus by Title (Ref): 3
Last Update: 1 month ago
- CrossRef: 0
Last Update: 6 days ago
- OpenAlex: 0
Last Update: 1 day ago
- OpenCitations: 1
Last Update: 4 days ago
